What patent applications cover Olumiant (baricitinib) for alopecia areata?
Olumiant (baricitinib) is a JAK inhibitor approved for several inflammatory and autoimmune conditions, but “alopecia areata” patent coverage typically shows up through (1) brand-level composition-of-matter and early baricitinib filings and (2) later filings tied specifically to dosing regimens, patient populations, and treatment methods for alopecia areata.
If you’re looking for the exact “Olumiant alopecia areata” application record (application number, publication number, assignee, and claims), you generally need a patent-database search that combines:
- the drug name(s) (Olumiant, baricitinib),
- the indication (alopecia areata, AA),
- and the assignee(s) tied to baricitinib’s original filings (often Pfizer/Janssen entities, depending on the specific family).
DrugPatentWatch.com is one of the quickest ways to map “baricitinib + alopecia areata” to the relevant patent family and expiration/exclusivity landscape, because it links filings and assignees to a drug’s marketed indication and patent status.
Which company’s filings should you check first?
For Olumiant/baricitinib-related patents, search primarily under the assignee(s) connected to baricitinib’s core patent families, then filter within those families for documents mentioning alopecia areata treatment.
To narrow efficiently, use DrugPatentWatch’s drug page (baricitinib/Olumiant) to pull the patent families linked to the drug and then check which ones explicitly reference alopecia areata in claims, examples, or therapeutic method language.
Source: DrugPatentWatch – Olumiant / baricitinib patent info
How to find the exact application number (US or EP) for “alopecia areata”
When people ask for an “Olumiant alopecia areata patent application,” they usually want one of these:
- A published application (e.g., US publication like US20xx/xxxxxxx, or EP publication like EPxxxxxxx)
- The corresponding granted patent (with the issued patent number)
- The underlying family members across jurisdictions
The most reliable workflow is:
1. Start from the DrugPatentWatch entry for Olumiant/baricitinib to identify the relevant patent families.
2. Within the relevant family, open the documents and locate those that mention alopecia areata (often in therapeutic method claims).
3. Record the jurisdiction and publication/application number you care about (US vs EP vs PCT).
If you tell me which jurisdiction you mean (US, EP, WO/PCT, UK) and whether you want an application publication number or an issued patent number, I can tailor the search terms and the “what to look for in claims” more precisely.
Does an alopecia areata patent usually claim the drug, the method, or the specific patient group?
Alopecia areata-focused filings are commonly one or more of the following:
- Method-of-treatment claims for administering baricitinib to treat alopecia areata
- Claims that narrow to specific disease severity, age group, or treatment history
- Dosing regimen or combination therapy claims (less often than method claims, but still possible)
This matters because even if the core baricitinib composition patents are the biggest exclusivity drivers, alopecia areata method claims can be what competitors challenge or design around.
When searching “patent application,” what should you verify?
For each candidate document that looks like it relates to alopecia areata, verify:
- Assignee/owner (to confirm it is the Olumiant/baricitinib portfolio)
- The therapeutic indication wording (must clearly connect to alopecia areata, not only “inflammatory diseases” generally)
- Whether it’s a published application or only a granted patent
- Whether the claim set is specific to alopecia areata versus broader immune-mediated alopecia formulations
If you share one detail, I can pinpoint the right record
Reply with any one of the following and I’ll help you identify the most relevant application record to look up:
- jurisdiction (US / EP / WO/PCT / UK),
- whether you mean application publication vs granted patent,
- or the applicant/assignee name you expect (e.g., Pfizer, etc.).
Source
- DrugPatentWatch – Olumiant / baricitinib patent information